Merck (NYSE:MRK) and LaNova Medicines announced Thursday an agreement under which the U.S. pharmaceutical giant is expected ...

Minghui Pharmaceutical has reported promising initial outcomes from its Phase I trial of MHB039A to treat patients with ...

The following is a summary of "Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and ...

Merck & Co. has struck a licensing deal with LaNova Medicines that is potentially worth more than $3 billion to the clinical-stage biotechnology company.

Keytruda is a biologic that belongs to the programmed cell death protein 1 (PD-1) inhibitor drug class. Read on to learn about potential common, mild, and serious side effects of Keytruda.

Scientists investigated how an inherited genetic variation common among East Asians contributes to drug resistance in cancer cells, driving more aggressive cancer growth. The team trialled a precision ...

Gotistobart is a next-generation anti-cytotoxic T-lymphocyte-associated protein 4 antibody candidate ... despite prior treatment with a programmed cell death protein 1 or programmed death ligand ...